Bicara Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
BCAX$9.98+15.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except shares and per share data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets · (Unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $520,758 | $230,440 |
| Prepaid expenses and other assets | 756 | 633 |
| Total current assets | 521,514 | 231,073 |
| Property and equipment, net | 130 | 202 |
| Right of use asset – operating lease | 414 | 613 |
| Other assets | 2,115 | 2,094 |
| Total assets | $524,173 | $233,982 |
| Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,531 | $2,142 |
| Accounts payable – related party | 431 | 1,044 |
| Accrued expenses and other current liabilities | 10,410 | 8,053 |
| Accrued expenses and other current liabilities – related party | 1,801 | 3,561 |
| Operating lease liability – current portion | 308 | 285 |
| Total current liabilities | 14,481 | 15,085 |
| Operating lease liability – net of current portion | 137 | 372 |
| Other liabilities | — | 17 |
| Total liabilities | 14,618 | 15,474 |
| Commitments and Contingencies: | ||
| Seed Series redeemable convertible preferred stock, $0.0001 par value, 0 and 81,790,144 authorized; issued and outstanding as of September 30, 2024 and December 31, 2023, respectively (liquidation preference of $0 and $81,790 as of September 30, 2024, and December 31, 2023, respectively) | — | 81,525 |
| Series B redeemable convertible preferred stock, $0.0001 par value, 0 and 105,595,101 shares authorized; issued and outstanding as of September 30, 2024 and December 31, 2023, respectively (liquidation preference of $0 and $108,235 as of September 30, 2024 and December 31, 2023, respectively); | — | 121,148 |
| Series C redeemable convertible preferred stock, $0.0001 par value, 0 and 119,599,872 shares authorized; issued and outstanding as of September 30, 2024 and December 31, 2023, respectively (liquidation preference of $0 and $165,000 as of September 30, 2024 and December 31, 2023, respectively) | — | 164,604 |
| Total redeemable convertible preferred stock | — | 367,277 |
| Stockholders' equity (deficit): | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value, 500,000,000 and 365,000,000 shares authorized; 54,424,994 and 711,895 shares issued and 54,409,708 and 640,386 shares outstanding as of September 30, 2024 and December 31, 2023, respectively | 7 | 2 |
| Additional paid-in capital | 709,607 | 4,250 |
| Accumulated deficit | (200,059) | (153,021) |
| Total stockholders' equity (deficit) | 509,555 | (148,769) |
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $524,173 | $233,982 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.